Scientific article
OA Policy
English

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

Published in

The journal of antimicrobial chemotherapy, vol. 78, no. 5, p. 1191-1194

Publication date

2023-05-03

Abstract

Background: Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales. However, PBP3-modified and NDM-producing Escherichia coli strains that co-produce CMY-42 have been shown to be resistant to this drug combination. The aim of our study was to assess the in vitro activity of cefepime/taniborbactam and cefepime/zidebactam against such aztreonam/avibactam-resistant E. coli strains.

Methods: MIC values of aztreonam, aztreonam/avibactam, cefepime, cefepime/taniborbactam, cefepime/zidebactam and zidebactam alone were determined for 28 clinical aztreonam/avibactam-resistant E. coli isolates. Those isolates produced either NDM-5 (n = 24), NDM-4 (n = 2) or NDM-1 (n = 2), and they all co-produced CMY-42 (n = 28). They all harboured a four amino acid insertion in PBP-3 (Tyr-Arg-Ile-Asn or Tyr-Arg-Ile-Lys).

Results: All strains were resistant to aztreonam/avibactam and cefepime, as expected. The resistance rate to cefepime/taniborbactam was 100%, with MIC50 and MIC90 being at 16 mg/L and 64 mg/L, respectively. Conversely, all strains were susceptible to cefepime/zidebactam, with both MIC50 and MIC90 at 0.25 mg/L. Notably, all strains showed low MICs for zidebactam alone, with MIC50 and MIC90 at 0.5 mg/L and 1 mg/L.

Conclusions: Our data highlighted the excellent in vitro performance of the newly developed β-lactam/β-lactamase inhibitor combination cefepime/zidebactam against aztreonam/avibactam-resistant E. coli strains, suggesting that this combination could be considered as an efficient therapeutic option in this context. Our study also highlights the cross-resistance between acquired resistance to aztreonam/avibactam and the cefepime/taniborbactam combination.

Keywords

  • Aztreonam / pharmacology
  • Cefepime / pharmacology
  • Escherichia coli
  • Anti-Bacterial Agents / pharmacology
  • Beta-Lactamases / metabolism
  • Cephalosporins / pharmacology
  • Azabicyclo Compounds / pharmacology
  • Beta-Lactamase Inhibitors / pharmacology
  • Microbial Sensitivity Tests

Citation (ISO format)

LE TERRIER, Christophe et al. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. In: The journal of antimicrobial chemotherapy, 2023, vol. 78, n° 5, p. 1191–1194. doi: 10.1093/jac/dkad061

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0305-7453
47views
153downloads

Technical informations

Creation

03/11/2024 19:33:03

First validation

14/02/2025 09:45:35

Update

24/03/2026 08:56:00

Status update

24/03/2026 08:56:00

Last indexation

24/03/2026 08:57:39
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated